Clinical trials
Advanced Lung Cancer clinical trials
Below are recruiting advanced lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,319 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06698965RecruitingPhase 2
Study of trilaciclib, envafolimab, etoposide, and carboplatin for extensive-stage small cell lung cancer
This trial tests a combination of four drugs as a first treatment for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and effective. It may be an option for those who have not had prior treatment for advanced disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07330596RecruitingPhase 2
Study of QL1706 plus chemo for lung cancer that got worse after immunotherapy
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
HefeiAges 18–75 - NCT06596915RecruitingPhase 1
BA1302 for advanced solid tumors
This trial tests a new drug, BA1302, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if BA1302 is safe and effective.
BeijingAges 18 years+ - NCT06545331RecruitingPhase 1
A study of XB010 for advanced solid tumors
This trial tests an investigational drug called XB010 for people with solid tumors that have spread or cannot be removed by surgery. It aims to see if XB010 is safe and effective for several cancer types, including lung, breast, head and neck, and esophageal cancers.
Irvine, CaliforniaAges 18 years+ - NCT06244771RecruitingPhase 1/Phase 2
Testing FMC-376 for KRAS G12C mutated solid tumors
This study tests a new targeted pill called FMC-376 for people whose cancer has a specific KRAS G12C mutation. The goal is to see if it can shrink tumors or slow their growth when other treatments have stopped working.
La Jolla, CaliforniaAges 18 years+ - NCT06621563RecruitingPhase 1
Study of HS-20117 Combination Therapy for Advanced Solid Tumors
This early-phase trial tests a new drug (HS-20117) combined with other drugs for people with advanced solid tumors. It aims to see if the combination is safe and effective, especially for cancers that have not responded to other treatments.
TianjinAges 18–75 - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT07278479RecruitingPhase 1/Phase 2
Study of a targeted radiation therapy for small cell lung cancer
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
Atlanta, GeorgiaAges 18 years+ - NCT06829459RecruitingPhase 3
New drug combo vs chemo for resistant lung cancer
This trial tests a combination of two targeted drugs (Glumetinib and Osimertinib) against standard chemotherapy for people with non-small cell lung cancer that has stopped responding to initial targeted therapy. It may be an option if your tumor has a specific genetic change called MET amplification or overexpression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06370416Enrolling by invitationPhase 2
Preventing bone marrow suppression from chemo in advanced lung cancer
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
Zhengzhou, HenanAges 18 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Sacramento, CaliforniaAges 18 years+ - NCT07668752RecruitingPhase 3
New pill (GFH375) vs chemo for KRAS G12D lung cancer
This study tests a new pill (GFH375) against a standard chemotherapy (docetaxel) for advanced lung cancer with a specific KRAS G12D mutation. If you have already tried platinum chemo and an immunotherapy, this trial might offer a new option.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06154538RecruitingPhase 2
Immunotherapy plus chemo vs. chemo alone for advanced colorectal cancer before surgery
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced colorectal cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06380816RecruitingPhase 1/Phase 2
Study of UCB4594 for advanced cancers with HLA-G marker
This trial tests an experimental drug called UCB4594 for people with certain advanced cancers that have not responded to standard treatments. The goal is to see if the drug is safe and effective against tumors that have a specific marker called HLA-G.
LondonAges 18 years+ - NCT06109558RecruitingPhase 1/Phase 2
LMV-12 plus Osimertinib for advanced lung cancer
This trial tests a new drug called LMV-12 combined with osimertinib for people with advanced non-small cell lung cancer that has certain genetic changes (MET amplification or RET fusion) and has stopped responding to standard EGFR inhibitor treatments.
Changsha, HunanAges 18 years+ - NCT07100080RecruitingPhase 2/Phase 3
New drug vs chemotherapy for EGFR-mutated lung cancer
This trial tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy (platinum plus pemetrexed) for people with a specific type of lung cancer that has an EGFR mutation and has stopped responding to newer targeted pills.
Irvine, CaliforniaAges 18 years+ - NCT06376097Recruiting
Lung cancer screening with low-dose CT and a blood test
This study tests a lung cancer screening program using low-dose CT scans and a blood test to find cancer early. It is for people who smoke or used to smoke.
Botucatu, São PauloAges 45–74 - NCT06116682RecruitingPhase 2
Targeted treatment for MET-positive advanced lung cancer
This trial tests a targeted therapy for people with advanced non-small cell lung cancer whose tumors have extra copies of the MET gene. It's for those whose cancer has progressed after at least one prior treatment.
Jonesboro, ArkansasAges 18 years+ - NCT06846437RecruitingPhase 3
New drug JSKN003 vs. Kadcyla for HER2-positive advanced breast cancer
This trial compares a new targeted therapy (JSKN003) against Kadcyla (T-DM1) for people with HER2-positive breast cancer that has advanced or spread. Both drugs work by attaching a chemotherapy directly to HER2-positive cancer cells, and the study aims to see if the new drug works better or has fewer side effects.
ShanghaiAges 18 years+ - NCT06946927RecruitingPhase 1
Study of JMKX001899 with other drugs for advanced KRAS G12C lung cancer
This trial tests a new targeted therapy, JMKX001899, combined with other treatments for advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It aims to see if this combination can help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT06362980RecruitingPhase 1
BPI-1178 plus osimertinib for EGFR-mutated lung cancer
This trial tests a new drug (BPI-1178) combined with osimertinib for advanced lung cancer with EGFR mutations. It’s for people whose cancer has progressed after prior treatment with a third-generation EGFR targeted therapy.
BeijingAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT07391813RecruitingPhase 1/Phase 2
Testing SNB-101 for advanced small cell lung cancer
This study tests a new drug, SNB-101, for people with small cell lung cancer that has spread and has worsened after standard therapy. It aims to find out if SNB-101 can help control the cancer and what side effects it may cause.
KamenitzAges 18 years+ - NCT07202611RecruitingPhase 2
Immune Cell Therapy for Advanced Lung Cancer
This study tests a new kind of cancer treatment using your own immune cells (called DC and NK cells) to fight advanced non-small cell lung cancer. It's for people who have already tried other treatments but need more options.
Huwei, YUNLINAges 20 years+
Hear when a new Advanced Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced lung cancer?
- Yes. Clin2 currently lists 1,319 recruiting advanced lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- EGFR Mutant Advanced Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.